ALLOX closes $10.5M seed financing to scale drug discovery platform
ALLOX combines high-throughput genetics, experimental biology, and AI to target protein-protein interactions and transcription factors. The platform maps genetic mutations to identify regulatory regions within proteins that can serve as binding pockets for small-molecule drugs. This approach aims to unlock targets that were previously considered unreachable by conventional methods.
Key points
- Secured $10.5 million in seed funding led by Asabys.
- Combines AI with functional genetic data for drug discovery.
- Focuses on identifying allosteric and orthosteric regulatory sites in proteins.
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. Tech.eu did the reporting; read the original for the full story.
Read the full story at Tech.eu
